The advocacy for renaming polycystic ovary syndrome to ‘metabolic reproductive syndrome’ carries significant practical implications for clinical practice and patient care. First, the proposed terminology better captures the condition’s systemic nature, affecting metabolic, endocrine, and reproductive systems simultaneously. Second, understanding that only 20% of patients have ovarian cysts should fundamentally shift how healthcare providers approach diagnosis and treatment, prioritizing screening for metabolic dysfunction including insulin resistance in 70% of cases. Third, this nomenclature reform emphasizes the need for comprehensive care addressing cardiovascular risk factors, psychological symptoms affecting 50% of patients, and weight management issues. For patients, recognizing PCOS as a metabolic disorder may improve access to appropriate endocrinologic care and reduce diagnostic delays. Healthcare providers should adopt terminology reflecting disease mechanisms rather than anatomical labels, ensuring treatment strategies address the full scope of clinical manifestations.
Was this article helpful?
